Sab biotherapeutics to present at innodia annual meeting

Miami beach, fla., april 08, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq:  sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced their chief medical officer, dr. alexandra kropotova, md, mba will share an overview of the sab-142 clinical development plan and anticipated milestones at the innodia annual meeting in leuven, belgium on april 11, 2024.
SABS Ratings Summary
SABS Quant Ranking